1. Key Insights
2. Report Introduction
3. Chronic Pain Market Overview at a Glance
3.1. Market Share (%) Distribution of Chronic Pain in 2018
3.2. Market Share (%) Distribution of Chronic Pain in 2030
4. Executive Summary of Chronic Pain
5. Epidemiology and Market Methodology
6. Disease Background and Overview
6.1. Introduction
6.2. Types of Chronic Pain
6.2.1. Neuropathic Pain
6.2.2. Arthritis Pain
6.2.3. Cancer Pain
6.2.4. Fibromyalgia
6.2.5. Migraine
6.2.6. Chronic Low Back Pain (CLBP)
6.2.7. Postsurgical pain
6.3. Signs and symptoms of Chronic Pain
6.3.1. Symptoms of Fibromyalgia
6.3.2. Symptoms of Neuropathic Pain
6.3.3. Symptoms of Postsurgical Pain
6.3.4. Symptoms of Cancer Pain
6.3.5. Symptoms of Migraine
6.3.6. Symptoms of Arthritis Pain
6.4. Risk factors and causes of Chronic Pain
6.5. Pathophysiology of Chronic Pain
6.6. Genetics of Chronic Pain
6.7. Complications of Chronic Pain
7. Diagnosis of Chronic Pain
7.1. Physical, Neurological and Mental health exams
7.2. Blood tests and Urine Analysis
7.3. Imaging tests
7.3.1. X-Rays
7.3.2. Bone scan
7.3.3. Computed Tomography (CT) imaging
7.3.4. Magnetic Resonance Imaging
7.3.5. Myelogram
7.4. Nerve Tests
7.4.1. Electromyography (EMG)
7.4.2. Nerve Conduction Study
7.5. Differential Diagnosis
7.6. Diagnostic Guidelines
7.6.1. American Family Physician – Peripheral Neuropathy guidelines
7.6.2. NICE Guidelines for Lower Back Pain and Sciatica
7.6.3. American Pain Society – Guidelines for Postoperative Pain
7.6.4. Guidelines for clinical diagnosis of fibromyalgia
7.6.5. Diagnostic Guidelines from American Society of Anesthesiologists Task Force
8. Current Treatment
8.1. Treatment Algorithm
8.2. Neuropathic Pain
8.3. Rheumatoid Arthritis (RA)
8.4. Osteoarthritis (OA)
8.5. Fibromyalgia
8.6. Advanced Cancer Pain
8.7. Chronic Migraine Pain
8.8. Chronic Back Pain
8.9. Postsurgical Pain
8.10. Treatment Guidelines
8.10.1. Center for Disease Control and Prevention (CDC) Guidelines
8.10.2. American College of Physicians (ACP) Guidelines
8.10.3. NICE Guidelines
8.10.4. American Society of Anesthesiologists Task Force on Chronic Pain Management
8.10.5. WHO Pain Ladder for Advanced Cancer Pain
8.10.6. ESMO Clinical Practice Guidelines
8.10.7. Spanish Guidelines
8.10.8. Department of Veterans Af airs and the Department of Defense (VA/DoD) clinical practice guideline for opioid therapy for chronic pain
8.10.9. European Pain Federation guidelines on appropriate opioid use in chronic pain management
8.10.10. Guideline of the Japanese Society of Palliative Medicine for Pharmacological Management of Cancer Pain
9. Epidemiology and Patient Population
9.1. Key Findings
9.2. Epidemiology of Chronic Pain
9.3. Epidemiology Scenario: 7MM
9.3.1. Total Prevalent Cases of Chronic Pain
9.3.2. Total Diagnosed Cases of Chronic Pain
9.3.3. Total Age-specific Cases of Chronic Pain
9.3.4. Cause-specific Cases of Chronic Pain
9.3.5. Severity-specific Cases of Chronic Pain
9.3.6. Total Treated Cases of Chronic Pain
10. The United States
10.1. Total Prevalent Cases of Chronic Pain
10.2. Total Diagnosed Cases of Chronic Pain
10.3. Total Age-specific Cases of Chronic Pain
10.4. Cause-specific Cases of Chronic Pain
10.5. Severity-specific Cases of Chronic Pain
10.6. Total Treated Cases of Chronic Pain
11. EU-5
11.1. Germany
11.1.1. Total Prevalent Cases of Chronic Pain
11.1.2. Total Diagnosed Cases of Chronic Pain
11.1.3. Total Age-specific Cases of Chronic Pain
11.1.4. Cause-specific Cases of Chronic Pain
11.1.5. Severity-specific Cases of Chronic Pain
11.1.6. Total Treated Cases of Chronic Pain
11.2. France
11.2.1. Total Prevalent Cases of Chronic Pain
11.2.2. Total Diagnosed Cases of Chronic Pain
11.2.3. Total Age-specific Cases of Chronic Pain
11.2.4. Cause-specific Cases of Chronic Pain
11.2.5. Severity-specific Cases of Chronic Pain
11.2.6. Total Treated Cases of Chronic Pain
11.3. Italy
11.3.1. Total Prevalent Cases of Chronic Pain
11.3.2. Total Diagnosed Cases of Chronic Pain
11.3.3. Total Age-specific Cases of Chronic Pain
11.3.4. Cause-specific Cases of Chronic Pain
11.3.5. Severity-specific Cases of Chronic Pain
11.3.6. Total Treated Cases of Chronic Pain
11.4. Spain
11.4.1. Total Prevalent Cases of Chronic Pain
11.4.2. Total Diagnosed Cases of Chronic Pain
11.4.3. Total Age-specific Cases of Chronic Pain
11.4.4. Cause-specific Cases of Chronic Pain
11.4.5. Severity-specific Cases of Chronic Pain
11.4.6. Total Treated Cases of Chronic Pain
11.5. The United Kingdom
11.5.1. Total Prevalent Cases of Chronic Pain
11.5.2. Total Diagnosed Cases of Chronic Pain
11.5.3. Total Age-specific Cases of Chronic Pain
11.5.4. Cause-specific Cases of Chronic Pain
11.5.5. Severity-specific Cases of Chronic Pain
11.5.6. Total Treated Cases of Chronic Pain
12. Japan
12.1.1. Total Prevalent Cases of Chronic Pain
12.1.2. Total Diagnosed Cases of Chronic Pain
12.1.3. Total Age-specific Cases of Chronic Pain
12.1.4. Cause-specific Cases of Chronic Pain
12.1.5. Severity-specific Cases of Chronic Pain
12.1.6. Total Treated Cases of Chronic Pain
13. Patient Journey
14. Key Endpoints in Chronic Pain Clinical Trials
15. Marketed Therapies
15.1. Emgality (Galcanezumab): Elli Lilly and Company
15.1.1. Drug Description
15.1.2. Regulatory Milestones
15.1.3. Other Developmental Activities
15.1.4. Pivotal Clinical Trial
15.1.5. Ongoing Current Pipeline Activity
15.2. Savella (Milnacipran): Allergan (acquired by AbbVie)
15.2.1. Drug Description
15.2.2. Regulatory Milestones
15.2.3. Other Developmental Activities
15.2.4. Pivotal Clinical Trial
15.3. Vyepti (Eptinezumab): Alder Biopharmaceuticals (Acquired by Lundbeck)
15.3.1. Product Description
15.3.2. Regulatory Milestones
15.3.3. Other Developmental Activities
15.3.4. Pivotal Clinical Trial
15.4. Tarlige (Mirogabalin): Daiichi Sankyo
15.4.1. Product Description
15.4.2. Regulatory Milestones
15.4.3. Other Developmental Activities
15.4.4. Pivotal Clinical Trial
15.5. Aimovig (Erenumab): Amgen/Novartis
15.5.1. Product Profile
15.5.2. Regulatory Milestones
15.5.3. Other Developmental Activities
15.5.4. Pivotal Clinical Trials
15.5.5. Ongoing Current Pipeline Activity
15.6. Ajovy (Fremanezumab): Teva Pharmaceuticals
15.6.1. Product Description
15.6.2. Regulatory Milestones
15.6.3. Other Developmental Activities
15.6.4. Pivotal Clinical Trials
16. Emerging Therapies
16.1. Tanezumab: Pfizer and Eli Lilly and Company
16.1.1. Drug Description
16.1.2. Other Developmental Activities
16.1.3. Clinical Development
16.1.4. Safety and Efficacy
16.2. Fasinumab (MT-5547, REGN475, SAR164877): Regeneron, Teva Pharmaceuticals, and Mitsubishi Tanabe Pharma Corporation
16.2.1. Drug Description
16.2.2. Other Developmental Activities
16.2.3. Clinical Development
16.2.4. Safety and Efficacy
16.3. Atogepant: Allergan (acquired by ABBVie)
16.3.1. Drug Description
16.3.2. Other Developmental Activities
16.3.3. Clinical Development
16.4. STA363: Stayble Therapeutics
16.4.1. Drug Description
16.4.2. Other Developmental Activities
16.4.3. Clinical Development
16.4.4. Safety and Efficacy
16.5. NYX-2925: Aptinyx
16.5.1. Drug Description
16.5.2. Other Developmental Activities
16.5.3. Clinical Development
16.5.4. Safety and Efficacy
16.6. LAT8881: Lateral Pharma
16.6.1. Drug Description
16.6.2. Other Developmental Activities
16.6.3. Clinical Development
16.7. LY-3451838: Eli Lilly and Company
16.7.1. Drug Description
16.7.2. Clinical Development
16.8. Lorecivivint (SM04690): Samumed
16.8.1. Drug Description
16.8.2. Other Developmental Activities
16.8.3. Clinical Development
16.8.4. Safety and Efficacy
16.9. RTX (MCP-101; Resiniferatoxin): Sorrento Therapeutics
16.9.1. Product Description
16.9.2. Other Developmental Activities
16.9.3. Clinical Development
16.9.4. Safety and Efficacy
16.10. Ampion: Ampio Pharmaceuticals
16.10.1. Product Description
16.10.2. Other Developmental Activities
16.10.3. Clinical Development
16.10.4. Safety and Efficacy
16.11. SP-102 (Semdexa): Semnur Pharmaceuticals
16.11.1. Product Description
16.11.2. Other Developmental Activities
16.11.3. Clinical Development
16.11.4. Safety and Efficacy
16.12. CAM2038: Braeburn Pharmaceuticals and Camurus
16.12.1. Drug Description
16.12.2. Other Developmental Activities
16.12.3. Clinical Development
16.12.4. Safety and Efficacy
16.13. TLC599: Taiwan Liposome Company
16.13.1. Product Description
16.13.2. Other Developmental Activities
16.13.3. Clinical Development
16.14. CNTX-4975: Centrexion Therapeutics
16.14.1. Product Description
16.14.2. Other Developmental Activities
16.14.3. Clinical Development
16.14.4. Safety and Efficacy
16.15. Vixotrigine (BIIB074): Biogen
16.15.1. Drug Description
16.15.2. Other Developmental Activities
16.15.3. Clinical Development
16.15.4. Safety and Efficacy
16.16. ALLOD-2: Allodynic Therapeutics
16.16.1. Product Description
16.16.2. Other Developmental Activities
16.16.3. Clinical Development
16.17. LX9211: Lexicon Pharmaceuticals
16.17.1. Product Description
16.17.2. Other Developmental Activities
16.17.3. Clinical Development
16.17.4. Safety and Efficacy
16.18. LY3556050: Eli Lilly and Company
16.18.1. Product Description
16.18.2. Clinical Development
16.19. Rexlemestrocel (MPC-06-ID): Gruenthal and Mesoblast
16.19.1. Product Description
16.19.2. Other Developmental Activities
16.19.3. Clinical Development
16.19.4. Safety and Efficacy
16.20. LY3016859: Eli Lilly and Company
16.20.1. Drug Description
16.20.2. Clinical Development
16.20.3. Safety and Efficacy
16.21. Ricolinostat (ACY-1215): Regenacy Pharmaceuticals
16.21.1. Drug Description
16.21.2. Other Developmental Activities
16.21.3. Clinical Development
16.22. AP-325: Algiax Pharmaceuticals
16.22.1. Product Description
16.22.2. Other Developmental Activities
16.22.3. Clinical Development
16.23. BAY1817080 (Eliapixant): Bayer
16.23.1. Product Description
16.23.2. Clinical Development
16.24. VX-150: Vertex Pharmaceuticals
16.24.1. Product Description
16.24.2. Clinical Development
16.24.3. Safety and Efficacy
16.25. Omnitram (Desmetramadol): Syntrix Biosystems
16.25.1. Drug Description
16.25.2. Other Developmental Activities
16.25.3. Clinical Development
16.26. NFX88: Neurofix Pharma
16.26.1. Drug Description
16.26.2. Other Developmental Activities
16.26.3. Clinical Development
16.27. AminoFix (dHACM): MiMedx
16.27.1. Drug Description
16.27.2. Other Developmental Activities
16.27.3. Clinical Development
17. Chronic Pain: 7 Major Market Analysis
17.1. Key Findings
17.2. Market Outlook
17.3. 7MM Market Size
17.3.1. Total Market Size of Chronic Pain in the 7MM
17.3.2. Market Size of Chronic Pain by Therapies in the 7MM
18. The United States Market Size
18.1. Total Market Size of Chronic Pain in the United States
18.2. Market Size of Chronic Pain by Therapies in the United States
19. EU-5 Market Size
19.1. Germany
19.1.1. Total Market size of Chronic Pain in Germany
19.1.2. Market Size of Chronic Pain by Therapies in Germany
19.2. France
19.2.1. Total Market size of Chronic Pain in France
19.2.2. Market Size of Chronic Pain by Therapies in France
19.3. Italy
19.3.1. Total Market size of Chronic Pain in Italy
19.3.2. Market Size of Chronic Pain by Therapies in Italy
19.4. Spain
19.4.1. Total Market size of Chronic Pain in Spain
19.4.2. Market Size of Chronic Pain by Therapies in Spain
19.5. The United Kingdom
19.5.1. Total Market size of Chronic Pain in the United Kingdom
19.5.2. Market Size of Chronic Pain by Therapies in the United Kingdom
20. Japan
20.1. Total Market size of Chronic Pain in Japan
20.2. Market Size of Chronic Pain by Therapies in Japan
21. Market Access and Reimbursement
21.1. Key HTA decisions for Chronic Pain
21.2. Patient Access Programs
22. Market Drivers
23. Market Barriers
24. SWOT Analysis
25. Unmet Needs
26. Appendix
26.1. Bibliography
26.2. Report Methodology
27. DelveInsight Capabilities
28. Disclaimer
29. About DelveInsight
List of Table
Table 1: Summary of Chronic Pain, Market, Epidemiology, and Key Events (2018–2030)
Table 2: Pain classifications
Table 3: Genes reported in genetic association studies of chronic pain conditions
Table 4: Diagnostic Guidelines
Table 5: Diagnostic Guidelines
Table 6: Diagnostic Guidelines
Table 7: Preventive measures
Table 8: Pharmacological treatments for pain
Table 9: WHO pain ladder
Table 10: Total Prevalent Cases of Chronic Pain in the 7MM (2018–2030)
Table 11: Total Diagnosed Cases of Chronic Pain in the 7MM (2018–2030)
Table 12: Total Age-specific Cases of Chronic Pain in the 7MM (2018–2030)
Table 13: Cause-specific Cases of Chronic Pain in the 7MM (2018–2030)
Table 14: Severity-specific Cases of Chronic Pain in the 7MM (2018–2030)
Table 15: Total Treated Cases of Chronic Pain in the 7MM (2018–2030)
Table 16: Total Prevalent Cases of Chronic Pain in the United States (2018–2030)
Table 17: Total Diagnosed Cases of Chronic Pain in the United States (2018–2030)
Table 18: Total Age-specific Cases of Chronic Pain in the United States (2018–2030)
Table 19: Cause-specific Cases of Chronic Pain in the United States (2018–2030)
Table 20: Severity-specific Cases of Chronic Pain in the United States (2018–2030)
Table 21: Total Treated Cases of Chronic Pain in the United States (2018–2030)
Table 22: Total Prevalent Cases of Chronic Pain in Germany (2018–2030)
Table 23: Total Diagnosed Cases of Chronic Pain in Germany (2018–2030)
Table 24: Total Age-specific Cases of Chronic Pain in Germany (2018–2030)
Table 25: Cause-specific Cases of Chronic Pain in Germany (2018–2030)
Table 26: Severity-specific Cases of Chronic Pain in Germany (2018–2030)
Table 27: Total Treated Cases of Chronic Pain in Germany (2018–2030)
Table 28: Total Prevalent Cases of Chronic Pain in France (2018–2030)
Table 29: Total Diagnosed Cases of Chronic Pain in France (2018–2030)
Table 30: Total Age-specific Cases of Chronic Pain in France (2018–2030)
Table 31: Cause-specific Cases of Chronic Pain in France (2018–2030)
Table 32: Severity-specific Cases of Chronic Pain in France (2018–2030)
Table 33: Total Treated Cases of Chronic Pain in France (2018–2030)
Table 34: Total Prevalent Cases of Chronic Pain in Italy (2018–2030)
Table 35: Total Diagnosed Cases of Chronic Pain in Italy (2018–2030)
Table 36: Total Age-specific Cases of Chronic Pain in Italy (2018–2030)
Table 37: Cause-specific Cases of Chronic Pain in Italy (2018–2030)
Table 38: Severity-specific Cases of Chronic Pain in Italy (2018–2030)
Table 39: Total Treated Cases of Chronic Pain in Italy (2018–2030)
Table 40: Total Prevalent Cases of Chronic Pain in Spain (2018–2030)
Table 41: Total Diagnosed Cases of Chronic Pain in Spain (2018–2030)
Table 42: Total Age-specific Cases of Chronic Pain in Spain (2018–2030)
Table 43: Cause-specific Cases of Chronic Pain in Spain (2018–2030)
Table 44: Severity-specific Cases of Chronic Pain in Spain (2018–2030)
Table 45: Total Treated Cases of Chronic Pain in Spain (2018–2030)
Table 46: Total Prevalent Cases of Chronic Pain in the United Kingdom (2018–2030)
Table 47: Total Diagnosed Cases of Chronic Pain in the United Kingdom (2018–2030)
Table 48: Total Age-specific Cases of Chronic Pain in the United Kingdom (2018–2030)
Table 49: Cause-specific Cases of Chronic Pain in the United Kingdom (2018–2030)
Table 50: Severity-specific Cases of Chronic Pain in the United Kingdom (2018–2030)
Table 51: Total Treated Cases of Chronic Pain in the United Kingdom (2018–2030)
Table 52: Total Prevalent Cases of Chronic Pain in Japan (2018–2030)
Table 53: Total Diagnosed Cases of Chronic Pain in Japan (2018–2030)
Table 54: Total Age-specific Cases of Chronic Pain in Japan (2018–2030)
Table 55: Cause-specific Cases of Chronic Pain in Japan (2018–2030)
Table 56: Severity-specific Cases of Chronic Pain in Japan (2018–2030)
Table 57: Total Treated Cases of Chronic Pain in Japan (2018–2030)
Table 58: Oswestry Disability Index
Table 59: Galcanezumab, Clinical Trial Description, 2021
Table 60: Aimvoig, Clinical Trial Description, 2021
Table 61: Tanezumab, Clinical Trial Description, 2021
Table 62: Fasinumab, Clinical Trial Description, 2021
Table 63: Atogepant, Clinical Trial Description, 2021
Table 64: STA363, Clinical Trial Description, 2021
Table 65: NYX-2925, Clinical Trial Description, 2021
Table 66: LAT8881, Clinical Trial Description, 2021
Table 67: LY-3451838, Clinical Trial Description, 2021
Table 68: Lorecivivint (SM04690), Clinical Trial Description, 2021
Table 69: RTX (MCP-101; Resinferatoxin),Clinical Trial Description, 2021
Table 70: Ampion, Clinical Trial Description, 2021
Table 71: SP-102, Clinical Trial Description, 2021
Table 72: CAM2038, Clinical Trial Description, 2021
Table 73: TLC599, Clinical Trial Description, 2021
Table 74: CNTX-4975, Clinical Trial Description, 2021
Table 75: BIIB074, Clinical Trial Description, 2021
Table 76: ALLOD-2, Clinical Trial Description, 2021
Table 77: LX9211, Clinical Trial Description, 2021
Table 78: LY3556050,Clinical Trial Description, 2021
Table 79: Rexlemestrocel (MPC-06-ID),Clinical Trial Description, 2021
Table 80: LY3016859, Clinical Trial Description, 2021
Table 81: Ricolinostat (ACY-1215), Clinical Trial Description, 2021
Table 82: AP-325Clinical Trial Description, 2021
Table 83: BAY1817080, Clinical Trial Description, 2021
Table 84: VX-150, Clinical Trial Description, 2021
Table 85: Patents for Omnitram
Table 86: Omnitram, Clinical Trial Description, 2021
Table 87: NFX88, Clinical Trial Description, 2021
Table 88: Patents for AmnioFix
Table 89: AmnioFix, Clinical Trial Description, 2021
Table 90: 7MM Market Size of Chronic Pain in USD Million (2018–2030)
Table 91: 7MM Market Size of Chronic Pain by Therapies in USD Million (2018–2030)
Table 92: The United States Market Size of Chronic Pain in USD Million (2018–2030)
Table 93: The United States Market Size of Chronic Pain by Therapies in USD Million (2018–2030)
Table 94: Germany Market Size of Chronic Pain in USD Million (2018–2030)
Table 95: Germany Market Size of Chronic Pain by Therapies in USD Million (2018–2030)
Table 96: France Market Size of Chronic Pain in USD Million (2018–2030)
Table 97: France Market Size of Chronic Pain by Therapies in USD Million (2018–2030)
Table 98: Italy Market Size of Chronic Pain in USD Million (2018–2030)
Table 99: Italy Market Size of Chronic Pain by Therapies in USD Million (2018–2030)
Table 100: Spain Market Size of Chronic Pain in USD Million (2018–2030)
Table 101: Spain Market Size of Chronic Pain by Therapies in USD Million (2018–2030)
Table 102: The United Kingdom Market Size of Chronic Pain in USD Million (2018–2030)
Table 103: The United Kingdom Market Size of Chronic Pain by Therapies in USD Million (2018–2030)
Table 104: Japan Market Size of Chronic Pain in USD Million (2018–2030)
Table 105: Japan Market Size of Chronic Pain by Therapies in USD Million (2018–2030)
Table 106: Key HTA Decisions for Chronic Pain
List of Figures
Figure 1: Epidemiology and Market Methodology
Figure 2: Understanding Chronic pain
Figure 3: Mechanism of postsurgical pain
Figure 4: Risk factors of Chronic Pain
Figure 5: Pathophysiology of chronic pain
Figure 6: Managing Chronic Pain in Adults
Figure 7: World Health Organization (WHO) analgesic Ladder
Figure 8: Total Prevalent Cases of Chronic Pain in the 7MM (2018–2030)
Figure 9: Total Diagnosed Cases of Chronic Pain in the 7MM (2018–2030)
Figure 10: Total Age-specific Cases of Chronic Pain in the 7MM (2018–2030)
Figure 11: Cause-specific Cases of Chronic Pain in the 7MM (2018–2030)
Figure 12: Severity-specific Cases of Chronic Pain in the 7MM (2018–2030)
Figure 13: Total Treated Cases of Chronic Pain in the 7MM (2018–2030)
Figure 14: Total Prevalent Cases of Chronic Pain in the United States (2018–2030)
Figure 15: Total Diagnosed Cases of Chronic Pain in the United States (2018–2030)
Figure 16: Total Age-specific Cases of Chronic Pain in the United States (2018–2030)
Figure 17: Cause-specific Cases of Chronic Pain in the United States (2018–2030)
Figure 18: Severity-specific Cases of Chronic Pain in the United States (2018–2030)
Figure 19: Total Treated Cases of Chronic Pain in the United States (2018–2030)
Figure 20: Total Prevalent Cases of Chronic Pain in Germany (2018–2030)
Figure 21: Total Diagnosed Cases of Chronic Pain in Germany (2018–2030)
Figure 22: Total Age-specific Cases of Chronic Pain in Germany (2018–2030)
Figure 23: Cause-specific Cases of Chronic Pain in Germany (2018–2030)
Figure 24: Severity-specific Cases of Chronic Pain in Germany (2018–2030)
Figure 25: Total Treated Cases of Chronic Pain in Germany (2018–2030)
Figure 26: Total Prevalent Cases of Chronic Pain in France (2018–2030)
Figure 27: Total Diagnosed Cases of Chronic Pain in France (2018–2030)
Figure 28: Total Age-specific Cases of Chronic Pain in France (2018–2030)
Figure 29: Cause-specific Cases of Chronic Pain in France (2018–2030)
Figure 30: Severity-specific Cases of Chronic Pain in France (2018–2030)
Figure 31: Total Treated Cases of Chronic Pain in France (2018–2030)
Figure 32: Total Prevalent Cases of Chronic Pain in Italy (2018–2030)
Figure 33: Total Diagnosed Cases of Chronic Pain in Italy (2018–2030)
Figure 34: Total Age-specific Cases of Chronic Pain in Italy (2018–2030)
Figure 35: Cause-specific Cases of Chronic Pain in Italy (2018–2030)
Figure 36: Severity-specific Cases of Chronic Pain in Italy (2018–2030)
Figure 37: Total Treated Cases of Chronic Pain in Italy (2018–2030)
Figure 38: Total Prevalent Cases of Chronic Pain in Spain (2018–2030)
Figure 39: Total Diagnosed Cases of Chronic Pain in Spain (2018–2030)
Figure 40: Total Age-specific Cases of Chronic Pain in Spain (2018–2030)
Figure 41: Cause-specific Cases of Chronic Pain in Spain (2018–2030)
Figure 42: Severity-specific Cases of Chronic Pain in Spain (2018–2030)
Figure 43: Total Treated Cases of Chronic Pain in Spain (2018–2030)
Figure 44: Total Prevalent Cases of Chronic Pain in the United Kingdom (2018–2030)
Figure 45: Total Diagnosed Cases of Chronic Pain in the United Kingdom (2018–2030)
Figure 46: Total Age-specific Cases of Chronic Pain in the United Kingdom (2018–2030)
Figure 47: Cause-specific Cases of Chronic Pain in the United Kingdom (2018–2030)
Figure 48: Severity-specific Cases of Chronic Pain in the United Kingdom (2018–2030)
Figure 49: Total Treated Cases of Chronic Pain in the United Kingdom (2018–2030)
Figure 50: Total Prevalent Cases of Chronic Pain in Japan (2018–2030)
Figure 51: Total Diagnosed Cases of Chronic Pain in Japan (2018–2030)
Figure 52: Total Age-specific Cases of Chronic Pain in Japan (2018–2030)
Figure 53: Cause-specific Cases of Chronic Pain in Japan (2018–2030)
Figure 54: Severity-specific Cases of Chronic Pain in Japan (2018–2030)
Figure 55: Total Treated Cases of Chronic Pain in Japan (2018–2030)
Figure 56: Mechanism of action of Fasinumab
Figure 57: Mechanism of action of Lorecivivint
Figure 58: Mechanism of action of Ampion
Figure 59: Mechanism of action of Desmetramadol
Figure 60: Market Size of Chronic Pain in the 7MM, USD Million (2018–2030)
Figure 61: 7MM Market Size of Chronic Pain by Therapies in USD Million (2018–2030)
Figure 62: Market Size of Chronic Pain in the United States, USD Million (2018–2030)
Figure 63: The United States Market Size of Chronic Pain by Therapies in USD Million (2018–2030)
Figure 64: Market Size of Chronic Pain in Germany, USD Million (2018–2030)
Figure 65: Germany Market Size of Chronic Pain by Therapies in USD Million (2018–2030)
Figure 66: Market Size of Chronic Pain in France, USD Million (2018–2030)
Figure 67: France Market Size of Chronic Pain by Therapies in USD Million (2018–2030)
Figure 68: Market Size of Chronic Pain in Italy, USD Million (2018–2030)
Figure 69: Italy Market Size of Chronic Pain by Therapies in USD Million (2018–2030)
Figure 70: Market Size of Chronic Pain in Spain, USD Million (2018–2030)
Figure 71: Spain Market Size of Chronic Pain by Therapies in USD Million (2018–2030)
Figure 72: Market Size of Chronic Pain in the United Kingdom, USD Million (2018–2030)
Figure 73: The United Kingdom Market Size of Chronic Pain by Therapies in USD Million (2018–2030)
Figure 74: Market Size of Chronic Pain in Japan, USD Million (2018–2030)
Figure 75: Japan Market Size of Chronic Pain by Therapies in USD Million (2018–2030)
Figure 76: Market Drivers
Figure 77: Market Barrier